Изучены особенности фармакокинетических схем распределения координационных соединений германия с никотиновой кислотой (МИГУ-1) и оксиэтилидендифосфоната германия с никотиновой кислотой (МИГУ-4). Анализ гистерезиса показал, что замена в структуре БАВ германия на оксиэтилидендифосфонат германия привела к более быстрому распределению в тканях
головного мозга и печени после введения МИГУ-4 и более скорого появления фармакологического эффекта, поскольку отсутствует петля гистерезиса. График гистерезиса после введения обоих соединений в сердце имеет петлю, что свидетельствует о медленном обмене и появлении фармакологического эффекта значительно позже.
Objective. Сomparative characteristics of the distribution of MIGU-1 and MIGU-4 and the determination
of the central and peripheral chambers of the kinetic distribution scheme.
Materials and methods. After compounds intra-abdominal introduction to the “Vistar” line rat-males
140–150 g (at 37.5 mg/kg of germanium) in 0.25; 0.5; 1; 2; 4; 8; 24 hours blood plasma sampled,
brain, liver, heart. Сoncentration of complexes was determined by the extraction-photometric method.
Сhart of the ratio of the concentration of substances between blood plasma and other test tissues
were constructed. The obtained graphs made it possible to characterize the presence of a simultaneous
effect or its deformation.
Results. With the introduction of MIGU-4 concentration germanium between the blood plasma
and brain, liver, rapid distribution (no hysteresis loop) is carried out, which indicates the rapid achievement
of pharmacological effect, but with the introduction of MIGU-1 there is a hysteresis loop, which
indicates a slow exchange between tissues, so the pharmacological effect may manifest much later.
With the introduction of both BAS, the graph of the ratio of germanium content in the heart and blood
plasma has a hysteresis loop, it is a slow exchange between the tissues, so the pharmacological
effect may appear much later.
Conclusions. Studying the phenomenon of hysteresis made it possible in the brain, liver and heart
to reveal the features and speed of the processes of distribution of BAS MIGU-1 and MIGU-2, to predict
the time of onset of the pharmacological effect and side effects.
